




theranica


Prescribed Digital Therapeutics



**In a world with more
than billion people
suffering from episodic
or chronic pain...**



Use of pills...



... has become the default reaction,
resulting in **drug abuse, overuse, and addiction**

Imagine...

theranica



Clinically proven



Easy-to-use



Drug-free



Non-invasive



Connected device



Smartphone-
controlled


Imagine a change...

Imagine harnessing recent discoveries in neuroscience to offer safe, non-addictive drug-free therapies...



Innovative neuroscience technology

- Conditioned Pain Modulation (CPM) – descending **endogenous** pain inhibition mechanism, was found to be deficient among migraine patients
- Remote stimulus in upper arm designed to activate nociceptive nerve fibers
- Message processed in brainstem (PAG and RVM), and triggers CPM: increased release of **norepinephrine and serotonin** aborts or relieves pain source in the trigeminal cervical complex
- CPM is a strong, global, long-term, **self-analgesic**





Migraine

World's 2nd most common reason for work absenteeism

- Multiple symptoms: headache, disturbed vision, cognitive impairment, sensitivity to light, sound and smells, nausea, vertigo
- High prevalence: 12% of population, usually 16-60 y.o.
- Affects the most productive years in life
- Cureless disease. Preventive meds only reduce frequency of attacks.
- Acute meds needed to rapidly abort or relief attacks
- \$5B spent on migraine medication every year

theranica


Nerivio[®]

- FDA & CE authorized, prescribed for treating migraine
- Used upon onset of migraine symptoms, for 45 mins
- 12 treatments per “pack” (one unit)
- Fully operated by a (free) smartphone App
- Device and App collect data, process, and provide individual guidance to patients




Outstanding Clinical Data from multiple studies

Pain Relief post 2h



Pain Free post 2h



Highest clinical efficacy,
highest safety profile:


- No **systemic** side effects
- No concern of **drug-drug interaction**
- No **abuse** risk at any number of uses
- No risk of **medication overuse**

■ Nerivio – Yarnitsky et al, Headache, 2019
■ Triptans - Ferrari et al, The Lancet, 2001
■ Lasmiditan – Kuca et al, Neurology, 2018
■ Ubrogapant – Lipton et al, JAMA, 2019
■ Rimegepant – Lipton et al, NEJM, 2019

Confidential

Higher efficacy in adolescents

- 5M-6M adolescents with migraine in the US
- Greater unmet need – most prescribed meds not authorized for adolescents
- Physicians and parents are reluctant to use triptan (or other meds) at this age



Hershey et al. Pain medicine 2021



Recently Endorsed by





Received: 16 March 2021 | Accepted: 9 May 2021

DOI: 10.1111/head.14153

AHS CONSENSUS STATEMENT

The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice

Jessica Ailani MD¹ | Rebecca C. Burch MD²  | Matthew S. Robbins MD³  | on behalf of the Board of Directors of the American Headache Society⁴

¹Department of Neurology, Medstar Georgetown University Hospital, Washington, DC, USA

²Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

³Department of Neurology, Weill Cornell Medicine, New York, NY, USA

⁴American Headache Society, Mt Royal, NJ, USA

Abstract

Objective: To incorporate recent research findings, expert consensus, and patient perspectives into updated guidance on the use of new acute and preventive treatments for migraine in adults.

Background: The American Headache Society previously published a Consensus Statement on the use of newly introduced treatments for adults with migraine. This update, which is based on the expanded evidence base and emerging expert consensus concerning postapproval usage, provides practical recommendations in the

Remote electrical neuromodulation

The REN device achieves therapeutic effects by delivering transcutaneous electrical stimulation to the upper arm, which induces conditioned pain modulation and activates a descending endogenous analgesia.⁷³ It was FDA-cleared for the acute treatment of migraine in adults based on positive results in a randomized controlled clinical trial⁴⁵; it was cleared for the acute treatment of migraine and chronic migraine in patients aged 12 years and older based on data from an open-label, single-arm, multicenter study.⁷⁴ As with many nondrug therapeutic options, REN has shown good tolerability and safety in clinical trials; paresthesia in the area of the device was the most common side effect.^{45,46} This novel approach to acute treatment may also reduce the use of medications and consequent risk of medication-overuse headache.⁷⁰

No, it's not a TENS unit...

	Remote Electrical Neuromodulation (REN)	Transcutaneous Electrical Nerve Stimulation (TENS)
MOA	Descending Pain Inhibition: Conditioned Pain Modulation (CPM)	Ascending Pain Blocking: Gate Theory
Nerve Fibers	C and A δ Fibers	A β Fibers
Stimulated Sensory Tract	Nociceptive	Touch
Body location	Remote from Pain Location	At Pain Location
Typical Pulse Frequency	100 - 120 Hz	40 - 80 Hz
Typical Pulse Width	400 μ S	50 - 300 μ S
Impact	Global	Local
FDA Indication	Acute treatment of migraine	Muscle pain and general pain relief
Insurance code (HCPCS)	K1023	E0720

Data-centered platform for patient excellence



Digital Therapeutics for Disease Management

Patient journey and benefits

Treat

Monitor

Share

Improve Adherence

Maximize Efficacy

App guides patient for optimal "dosage"

Diary shows history, outcomes, trends

One-click share diary with HCP

Adherence analyzed, App sends tips for improvement

RWE demonstrates consistent efficacy over time



Personalized Engagement with Every Patient

- Patient behavior is analyzed using ML algorithms
- Individualized recommendations are made
- Personalized notifications are sent to patients
- Patient behavior is further analyzed to monitor improvement in adherence, efficacy, etc.

“You may want to try to increase your stimulation intensity by 5% or so.”



The therapy gives feedback to the patient

Already prescribed by 2,000 doctors to 20,000 patients in the US




"Nerivio has been life changing for my daughter, Jordan Odwyer"



"I have gotten my life back using Nerivio. My migraines aren't a disability anymore."



"The first treatment option that gives me the relief I need. Love the option to use it at night."



"Nerivio is amazing. It helps avoid taking heavy medication for your migraines. "


AN: "Nerivio has been a life saver. I typically use it on days where I am really severe. I usually can see results immediately"

K.M.: "Excellent! I can always count on it for migraine"

J.R.: "A great route to help with migraines instead of taking medication"



"Nerivio reduced my migraines by 50%. It's one of my go-to tools in my migraine toolkit."



"Nerivio is the best thing that ever happened to me. It really helps me feel so much better."



"Nerivio helps take the edge of my headaches so I can function during the day. "



"It is a miracle. During the 45 minutes treatment my headache completely stopped."


E.I.: "Nerivio consistently works to, if not clear my headache entirely, substantially reduce symptoms. This allows me to return to function- where in the past I would have lost days or weeks. This device is amazing!!"

A.K.: "It's Great 😊. I Love the treatment process. I get bad migraine headaches and Nerivio really helps."


<https://nerivio.co/reviews>

Online Telemedicine Platform

Allows patient to quickly get a prescription and have Nerivio sent home, with leaving home



Perfectly positioned for wide coverage by health insurance



- **Unique** HCPCS code granted by the *Centers for Medicare & Medicaid Services*
- Initial claims already covered (single-case agreements) by Payers at \$450-\$750 per unit
- Huge cost benefit for insurance plans compared with branded migraine drugs
- Advanced reimbursement agreement negotiations with 3 commercial plans
- Already covered by the Veteran Administration, providing free access to 9M US veterans

We don't stop at Migraine



Ongoing clinical
development
addressing
additional diseases



Combination of Israel and US Leadership



Shimon Eckhouse, PhD
Chairman & Co-founder



Alon Ironi
CEO & Co-founder



Ronen Jashek
COO & Co-founder



Eran Porat
CFO



Slava Barabash
VP R&D & Co-founder



Dagan Harris, PhD
VP Clinical & Regulatory



Alit Stark-Inbar, PhD
VP Medical Information



Liron Rabany, PhD
Chief Scientist

Theranica USA



Scott Szymanski
President USA



Diane Evon
Dir. Patient Excellence



Jen Stanton
Head of market access



Dave Duff
Head of marketing

theranica

Join us in making
the change.

